Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
73.62
+0.88 (1.21%)
At close: Jun 6, 2025, 4:00 PM
73.61
-0.01 (-0.01%)
After-hours: Jun 6, 2025, 6:56 PM EDT
Insmed Revenue
Insmed had revenue of $92.82M in the quarter ending March 31, 2025, with 22.94% growth. This brings the company's revenue in the last twelve months to $381.03M, up 20.77% year-over-year. In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth.
Revenue (ttm)
$381.03M
Revenue Growth
+20.77%
P/S Ratio
33.26
Revenue / Employee
$299,788
Employees
1,271
Market Cap
13.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
| Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
| Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
| Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
| Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
INSM News
- 3 days ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 10 days ago - Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference - PRNewsWire
- 17 days ago - Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study - PRNewsWire
- 4 weeks ago - Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 5 weeks ago - Baron Health Care Fund Q1 2025 Top Contributors And Detractors - Seeking Alpha
- 5 weeks ago - Insmed To Present at the BofA Securities 2025 Health Care Conference - PRNewsWire
- 6 weeks ago - Insmed: Poised For Transformation Beyond ARIKAYCE - Seeking Alpha